Department of Cardiology, Hebei Cangzhou Hospital of Integrated Traditional Chinese Medicine and Western Medicine, Cangzhou, Hebei, China.
Neurological Rehabilitation, Hebei Cangzhou Hospital of Integrated Traditional Chinese Medicine and Western Medicine, Cangzhou, Hebei, China.
Br J Hosp Med (Lond). 2024 Jul 30;85(7):1-10. doi: 10.12968/hmed.2024.0115. Epub 2024 Jul 25.
Rosuvastatin is a common lipid-lowering statin on the market, but its impact on the incidence of long-term cardiovascular events is not well clarified. This study aimed to explore the effects of rosuvastatin on serum asymmetric dimethylarginine (ADMA) levels and the incidence of long-term cardiovascular events in patients with hyperlipidaemia and H-type hypertension. This retrospective study included 158 patients with hyperlipidaemia and H-type hypertension who were treated in the Hebei Cangzhou Hospital of Integrated Traditional Chinese Medicine and Western Medicine from August 2015 to August 2016. The patients were divided into an occurrence group and a non-occurrence group according to the occurrence of long-term cardiovascular events following the resuvostatin treatment. The changes in blood lipids, blood pressure, serum ADMA levels and vascular endothelial function indexes before and after treatment were compared, and the effect of ADMA on the occurrence of long-term cardiovascular events and its predictive efficacy were analysed using the Spearman correlation test and receiver operating characteristics (ROC) curve. After treatment, the levels of serum total cholesterol, low-density lipoprotein cholesterol, triglyceride, serum ADMA and blood pressure became significantly lower ( < 0.001), with high-density lipoprotein cholesterol exhibiting no significant difference. Twenty-two cases developed long-term cardiovascular events after the treatment, with an incidence of 13.92%. The occurrence group had significantly higher serum ADMA levels than the non-occurrence group ( < 0.001). The rosuvastatin treatment also lowered the levels of endothelin-1 and high-sensitivity C-reactive protein and increased the nitric oxide level ( < 0.001). Spearman correlation analysis showed that serum ADMA levels were positively correlated with the occurrence of long-term cardiovascular events (r=0.462, < 0.001). Meanwhile, according to the ROC curve, serum ADMA had a good predictive efficacy for long-term cardiovascular events, with an area under the curve of 0.885 (95% confidence interval 0.808-0.963; < 0.001). Rosuvastatin can reduce ADMA levels and exert vascular protective effects. The increase in serum ADMA levels is closely related to the occurrence of long-term cardiovascular events in patients with hyperlipidaemia and H-type hypertension, serving as a potential clinical predictor to guide disease prevention and treatment.
瑞舒伐他汀是市场上常见的降脂他汀类药物，但它对长期心血管事件发生的影响尚未完全明确。本研究旨在探讨瑞舒伐他汀对血脂异常合并 H 型高血压患者血清不对称二甲基精氨酸（ADMA）水平及长期心血管事件发生的影响。
这项回顾性研究纳入了 2015 年 8 月至 2016 年 8 月在河北沧州中西医结合医院接受治疗的 158 例血脂异常合并 H 型高血压患者。根据瑞舒伐他汀治疗后长期心血管事件的发生情况，将患者分为发生组和未发生组。比较治疗前后血脂、血压、血清 ADMA 水平及血管内皮功能指标的变化，采用 Spearman 相关检验及受试者工作特征（ROC）曲线分析 ADMA 对长期心血管事件发生的影响及其预测效能。
治疗后，患者血清总胆固醇、低密度脂蛋白胆固醇、三酰甘油、血清 ADMA 及血压水平均显著降低（ < 0.001），高密度脂蛋白胆固醇无显著差异。治疗后 22 例发生长期心血管事件，发生率为 13.92%。发生组血清 ADMA 水平显著高于未发生组（ < 0.001）。瑞舒伐他汀治疗还降低了内皮素-1 和高敏 C 反应蛋白水平，提高了一氧化氮水平（ < 0.001）。Spearman 相关分析显示，血清 ADMA 水平与长期心血管事件的发生呈正相关（r=0.462， < 0.001）。同时，ROC 曲线显示，血清 ADMA 对长期心血管事件具有良好的预测效能，曲线下面积为 0.885（95%置信区间 0.808-0.963； < 0.001）。
瑞舒伐他汀可降低 ADMA 水平，发挥血管保护作用。血清 ADMA 水平升高与血脂异常合并 H 型高血压患者长期心血管事件的发生密切相关，可作为潜在的临床预测指标，指导疾病的防治。
